2,085
Views
30
CrossRef citations to date
0
Altmetric
Regulation

Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science

, PhD & , MSc

References

  • Abrams DI. 2018. The therapeutic effects of Cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 49:7–11. doi:10.1016/j.ejim.2018.01.003.
  • Agriculture Improvement Act of 2018. 2018. H.R. 2, 115th Cong., 2nd Sess.
  • Brenneisen R. 2007. Chemistry and analysis of phytocannabinoids and other Cannabis constituents. In: ElSohly MA, editor. Marijuana and the cannabinoids. Totowa, New Jersey, USA: Humana Press.
  • Code of Federal Regulations (CFR). 2019. Title 21 (3). Washington, D.C.: U.S. Government Printing Office.
  • Cogan PS. 2020. The ‘entourage effect’ or ‘hodge-podge hashish’: the questionable rebranding, marketing, and expectations of cannabis polypharmacy. Expert Rev Clin Pharmacol. 2020:1–11. doi:10.1080/17512433.2020.1721281
  • Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group. 2017. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 376 (21):2011–2020. doi:10.1056/NEJMoa1611618.
  • Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, GWPCARE3 Study Group, et al. 2018. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 378(20):1888–1897. doi:10.1056/NEJMoa1714631.
  • Dziwenka M, Coppock R, Alexander M, Palumbo E, Ramirez C, Lermer S. 2020. Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in sprague-dawley rats. Toxicol Rep. 7:376–385. doi:10.1016/j.toxrep.2020.02.014.
  • Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I. 2019. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules. 24(9):1694. doi:10.3390/molecules24091694.
  • FDA. 2018. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
  • Federal Register (FR). 1997. Washington, D.C.: U.S. Government Printing Office.
  • Ferrante C, Recinella L, Ronci M, Menghini L, Brunetti L, Chiavaroli A, Leone S, Di Iorio L, Carradori S, Tirillini B, et al. 2019. Multiple pharmacognostic characterization on hemp commercial cultivars: focus on inflorescence water extract activity. Food Chem Toxicol. 125:452–461. doi:10.1016/j.fct.2019.01.035. Epub 2019 Jan 31.
  • Food and Drug Administration (FDA). 2019. Presentations: FDA’s scientific data and information about products containing cannabis or cannabis-derived compounds public hearing [Internet]. U.S. Food and Drug Administration. Available from: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds
  • Friedman D, Sirven JI. 2017. Historical perspective on the medical use of cannabis for epilepsy: ancient times to the 1980s. Epilepsy Behav. 70(Pt B):298–301. doi:10.1016/j.yebeh.2016.11.033.
  • Gallily R, Yekhtin Z, Hanuš LO. 2015. Overcoming the bell‐shaped dose‐response of cannabidiol by using cannabis extract enriched in cannabidiol. PP. 06(02):75–85. doi:10.4236/pp.2015.62010.
  • Gallily R, Yekhtin Z, Hanuš LO. 2018. The anti-inflammatory properties of terpenoids from cannabis. Cannabis Cannabinoid Res. 3(1):282–290. doi:10.1089/can.2018.0014.
  • GlaxoSmithKline. 2014. Lovaza prescribing information. Research Triangle Park, North Carolina, USA: GlaxoSmithKline.
  • Greenwich Biosciences Inc. 2018. Epidiolex: Full prescribing information. Carlsbad, CA, USA: Greenwich Biosciences Inc.
  • Leas EC, Nobles AL, Caputi TL, Dredze M, Smith DM, Ayers JW. 2019. Trends in Internet Searches for Cannabidiol (CBD) in the United States. JAMA Netw Open. 2(10):e1913853. doi:10.1001/jamanetworkopen.2019.13853.
  • Long J. 2020. FDA head: it’s ‘fool’s game’ to tell people they can’t use CBD [Internet]. Natural Products INSIDER. Available from: https://www.naturalproductsinsider.com/regulatory/fda-head-its-fools-game-tell-people-they-cant-use-cbd.
  • Marx TK, Reddeman R, Clewell AE, Endres JR, Béres E, Vértesi A, Glávits R, Hirka G, Szakonyiné IP. 2018. An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp. J Toxicol. 2018:8143582doi:10.1155/2018/8143582.
  • Pamplona FA, da Silva LR, Coan AC. 2018. Potential clinical benefits of CBD-rich cannabis extracts over purified cbd in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 9:759.
  • Ranalli P, Venturi G. 2004. Hemp as a raw material for industrial applications. Euphytica. 140(1-2):1–6. doi:10.1007/s10681-004-4749-8.
  • Russo EB. 2019. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain”. No Gain. Front Plant Sci. 9:1969.
  • Technavio. 2019. CBD oil market by product and geography – forecast and analysis 2020–2024. Available from: https://www.technavio.com/report/cbd-oil-market-industry-analysis
  • Therapeutic Goods Administration. 2020. Safety of low dose cannabidiol. Available from: https://www.tga.gov.au/sites/default/files/review-safety-low-dose-cannabidiol.pdf
  • VanDolah HJ, Bauer BA, Mauck KF. 2019. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 94(9):1840–1851. doi:10.1016/j.mayocp.2019.01.003.
  • Zhou Y, Wang S, Ji J, Lou H, Fan P. 2018. Hemp (Cannabis sativa L.) Seed Phenylpropionamides Composition and Effects on Memory Dysfunction and Biomarkers of Neuroinflammation Induced by Lipopolysaccharide in Mice. ACS Omega. 3(11):15988–15995. doi:10.1021/acsomega.8b02250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.